SI-BONE (NASDAQ:SIBN) Receives “Overweight” Rating from Cantor Fitzgerald

SI-BONE (NASDAQ:SIBN)‘s stock had its “overweight” rating reiterated by investment analysts at Cantor Fitzgerald in a note issued to investors on Tuesday,Benzinga reports. They presently have a $25.00 target price on the stock. Cantor Fitzgerald’s price target suggests a potential upside of 36.75% from the stock’s current price.

Other equities analysts also recently issued reports about the company. Truist Financial raised their price target on SI-BONE from $16.00 to $18.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Needham & Company LLC boosted their price target on SI-BONE from $20.00 to $24.00 and gave the company a “buy” rating in a research note on Tuesday. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, SI-BONE has a consensus rating of “Buy” and an average target price of $23.83.

SI-BONE Price Performance

NASDAQ SIBN opened at $18.28 on Tuesday. The company has a debt-to-equity ratio of 0.22, a quick ratio of 7.22 and a current ratio of 8.25. The company has a market capitalization of $766.67 million, a price-to-earnings ratio of -20.76 and a beta of 1.17. The stock has a 50-day moving average of $15.73 and a 200 day moving average of $14.69. SI-BONE has a one year low of $11.70 and a one year high of $20.60.

SI-BONE (NASDAQ:SIBN) last released its quarterly earnings data on Monday, February 24th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.05. The firm had revenue of $49.00 million during the quarter, compared to analysts’ expectations of $48.87 million. SI-BONE had a negative net margin of 23.82% and a negative return on equity of 22.51%. On average, sell-side analysts forecast that SI-BONE will post -0.78 EPS for the current year.

Insider Buying and Selling at SI-BONE

In related news, CFO Anshul Maheshwari sold 5,304 shares of the stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $13.91, for a total value of $73,778.64. Following the completion of the sale, the chief financial officer now directly owns 189,319 shares of the company’s stock, valued at approximately $2,633,427.29. This represents a 2.73 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Anthony J. Recupero sold 3,670 shares of SI-BONE stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $13.90, for a total transaction of $51,013.00. Following the transaction, the insider now directly owns 222,814 shares in the company, valued at $3,097,114.60. This represents a 1.62 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 9,311 shares of company stock valued at $130,356. Company insiders own 3.90% of the company’s stock.

Institutional Trading of SI-BONE

A number of hedge funds and other institutional investors have recently modified their holdings of SIBN. Paradigm Capital Management Inc. NY increased its stake in SI-BONE by 5.3% in the 4th quarter. Paradigm Capital Management Inc. NY now owns 1,386,031 shares of the company’s stock worth $19,432,000 after buying an additional 69,831 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of SI-BONE by 8.3% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 102,666 shares of the company’s stock worth $1,439,000 after acquiring an additional 7,855 shares during the period. Virtus Fund Advisers LLC purchased a new stake in shares of SI-BONE during the fourth quarter worth about $40,000. Virtus Investment Advisers Inc. bought a new stake in SI-BONE during the 4th quarter valued at approximately $196,000. Finally, Squarepoint Ops LLC purchased a new position in SI-BONE in the 4th quarter worth approximately $449,000. 98.11% of the stock is owned by hedge funds and other institutional investors.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.